ARH-77 (B-lymphoblastoid cell line) was used as the immunogen for this CD86 antibody.
This antibody recognizes a protein of 70kDa, which is identified as CD86 (HLDA V, WS Code BP BP072. HLDA V, WS Code A A109. HLDA VI, WS Code BP 95. HLDA VI, WS Code B CD86.9). CD86 is a type I transmembrane glycoprotein and a member of the immunoglobulin superfamily of cell surface receptors. It is expressed at high levels on resting peripheral monocytes and dendritic cells and at very low density on resting B and T lymphocytes. CD86 expression is rapidly upregulated by Bcell specific stimuli with peak expression at 18 to 42 hours after stimulation. CD86, along with CD80/B71, is an important accessory molecule in Tcell co-stimulation via its interaction with CD28 and CD152/CTLA4. Since CD86 has rapid kinetics of induction, it is believed to be the major CD28 ligand expressed early in the immune response. It is also found on malignant Hodgkin and Reed Sternberg (HRS) cells in Hodgkins disease.
The concentration stated for each application is a general starting point. Variations in protocols, secondaries and substrates may require the CD86 antibody to be titered up or down for optimal performance.
IHC testing of FFPE human esophageal tumor stained with CD86 antibody (clone BU63).
FACS staining of human PBMCs using CD86 antibody (red, clone BU63) and isotype control (green).
Flow cytometry testing of PFA-fixed human Ramos cells with CD86 antibody (
* VAT and and shipping costs not included. Errors and price changes excepted
